Definitive Healthcare Corp. (DH): Results of Operations and Financial Condition
Definitive Healthcare Corp. (DH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dh-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Definitive Healthcare Reports Financial Results for Second Quarter 2026 Second Quarter Revenue Within Guidance Range; Profit Surpasses Expectations Framingham, MA (August 10, 2026) – Definitive Healthcare Corp. (“Definitive Hea
How this was made
The 30-second read
Why it matters
Traders can update near-term models using the provided Q3 and FY 2026 revenue, adjusted operating income, adjusted EBITDA, and adjusted net income per share ranges, and reassess margin and cash flow quality.
Market read
A primary earnings-and-guidance disclosure with quantified forward ranges and cash flow metrics, typically driving same-day repricing and next-week estimate revisions.
What to watch
Investors may focus on the gap between GAAP net loss and adjusted profitability, plus the sustainability of net dollar retention improvement and win-back momentum into FY 2026.
Background
The company filed an SEC Form 8-K (Item 2.02) with Exhibit 99.1 reporting Q2 2026 results and issuing forward guidance.
Ticker impact
Definitive Healthcare reported Q2 2026 revenue of $55.2M and issued Q3 2026 and FY 2026 guidance ranges in its 8-K.
Likely positive bias if investors view guidance and adjusted profitability as credible versus prior expectations; watch for sensitivity to revenue decline and EBITDA margin trajectory.
This is a primary disclosure (8-K with results and guidance) containing multiple quantified datapoints (revenue, adjusted EBITDA, FCF, and forward ranges). The article does not provide consensus comparisons, so magnitude of reaction is uncertain, but the direction is supported by “profit surpasses expectations” framing and positive cash flow.
Market effects
Healthcare data and analytics peers may see read-across on demand durability, retention, and AI product monetization, but this is company-specific.
Limited, as the disclosure is US-listed and not tied to a macro/regional policy change.
Low; no international regulatory or cross-border deal details are provided.
Counterpoint
Revenue declined year over year and adjusted EBITDA margin fell versus Q2 2025, so the “profit surpasses expectations” narrative may mask underlying deceleration.
Key entities
- companyDefinitive Healthcare Corp.
Nasdaq-listed healthcare market data and analytics provider reporting Q2 2026 results and guidance in an 8-K.
- executiveKevin Coop
CEO quoted on guidance discipline, net dollar retention improvement, and launch of the Turbo AI platform.
